Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

Annals of the Rheumatic Diseases

Volumn 58, Issue 4, 1999, Pages 220-225

  Dougados, Maxime ^a   Combe, Bernard ^b   Cantagrel, Alain ^c   Goupille, Philippe ^d   Olive, Patrick ^b   Schattenkirchner, Manfred ^e   Meusser, S ^f   Paimela, L ^g   Rau, Rolf ^h   Zeidler, Henning ⁱ   Leirisalo Repo, Marjatta ^j   Peldan, Kristiina ^k  

^a Hopital Cochin ^*  (France)

^b LAPEYRONIE HOSPITAL   (France)

^c CHU RANGUEIL   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Kivela Hospital   (Finland)

^h Evangelisches Fach krankenhaus Ratingen   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY OF HELSINKI   (Finland)

^k JORVI HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANALGESIC AGENT; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; BLOOD DYSCRASIA; BONE EROSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VAGINA BLEEDING;

EID: 0032957015     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.4.220     Document Type: Article

References (35)

1. 1 Emery P. Therapeutic approches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 1995;35 (suppl 2):87-90.
2. 2 Bendix G, Bjell A. Adding low dose cyclosporine A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1995;35: 1142-9.
3. 3 Faarvang KL, Egsmose C, Kryger P, et al. Hydroxychloroquine and sulfasalaxine alone and in combination in rheumatoid arthritis: a randomized double blind trial. Ann Rheum Dis 1993;52:711-15.
4. 4 Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. Arthritis Rheum 1994;37:1487-91.
5. 5 Ferraz MB, Pinheiro GR, Helfenstein M, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis, A multicenter randomized placebo-controlled trial. Scand J Rheumatol 1994;23:231-6.
6. 6 Haagsma CJ, van Riel PLCM, de Rooij DJRAM, et al. Combination of methotrexate and sulfasalaxine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy, Br J Rheumatol 1994;33:1049-55.
7. 7 Haagsma CJ, van Riel PLCM, de Jong AJL, van de Putte LBA. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
8. 8 Harris ED. The rationale for combination therapy of rheumatoid arthritis based on pathophysioloty. J Rheumatol 1996;23 (suppl 44):2-4.
9. 9 O'Dell J, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
10. 10 Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis: no benefit of addition of hydroxycloroquine to patients with suboptimal response to intramuscular gold theraw. J Rheumatol 1993;20:645-9.
11. 11 Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid athritis. N Engl J Med 1995;333:137-41.
12. 12 Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. Arthritis Rheum 1995;38:1799-806.
13. 13 van Zeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol 1996;23 (suppl 44):31-3.
14. 14 Pincus T, Callahan LF, Mitchell JM. Increased mortality in rheumatoid arthritis is explained in part on the basis of extensive comorbidity with other diseases. Arthritis Rheum 1987;30:S12.
15. 15 Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis, J Chronic Dis 1985;38:973-84.
16. 16 Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995;34:529-34.
17. 17 Gough A, Faint J, Wordworth P, Salmon M, Emery P. The HLA classII association of rheumatoid arthritis confers severity not susceptibility, (Abstract). Arthritis Rheum 1992;35:S47.
18. 18 van der Heijde D, van Riel PL, van Rijswijk MH, van de Putte LBA. Influence of prognostic features on the final outcome in rheumatoid arthritis; A review of the literature. Arthritis Rheum 1988;17:284-92.
19. 19 Arnett FC, Edworthy SM, Bloch A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
20. 20 van der Heijde D, van't Hof MA, van Riel PL, van de Putte L. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
21. 21 Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the as sessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
22. 22 Fries JF. The assessment of disability; from first to future principles. Br J Rheumatol 1983;22 (suppl ):48-58.
23. 23 Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
24. 24 Guillemin F, Briancon S, Pourel J. Mesure de la capacité fonctionnelle dans la polyarthrite rhumatoide: Adaptation française du Health Assessment Questionnaire (HAQ). Rev Rhum Mal Osteoartic 1991;58:459-65.
25. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the Preliminary American College of Rheumtology and the World Health Organization/ International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
26. 26 Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
27. 27 Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
28. 28 Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989;32:221-9.
29. 29 van der Heijde DM, van Riel PL, Nuver-Zwart HH, et al. Effects of hydroxychloroquine and sulphasalæine on progression of joint damage in rheumatoid arthritis. Lancet 1989;i:1036-8.
30. 30 van der Heijde D. Plain X-rays in rheumatoid arthritis: overviewing of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435-53.
31. 31 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10
32. 32 Emery P, Symmons DPM. What is early rheumatoid arthritis ?: Definition and diagnosis. Baillieres Clin Rheumatol 1997;11:23-6.
33. 33 Young A, van der Heijde D. Can we predict aggressive disease ? Baillieres Clin Rheumatol 1997;11:27-48.
34. 34 Healy LA, Wilske KR. Reforming the pyramid, A plan for treating rheumatoid arthritis in the 1990s. Rheum Dis Clin North Am 1989;15:615-19.
35. 35 Dougados M. Sulfasalazine. In: van de Putte LBA, Furst DE, Willimans HJ, et al, eds. Therapy of systemic rheumatic disorders. New York: Marcel Dekker, 1997:375-406.